How has been the historical performance of Ishita Drugs?

Answer:The historical performance of Ishita Drugs shows a mixed trend in financial metrics over the years. Breakdown: Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but an increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, remaining at 15.00 Cr in March 2025 compared to 15.19 Cr in the previous year. The company's total expenditure (excluding depreciation) was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, leading to an operating profit of 1.00 Cr, which is an increase from 0.91 Cr in March 2024. Profit before tax also rose to 1.16 Cr in March 2025 from 0.99 Cr in March 2024, resulting in a profit after tax of 0.87 Cr, up from 0.75 Cr the previous year. The earnings per share improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 2024, while total liabilities also rose to 16.30 Cr from 10.81 Cr, indicating a significant increase in both assets and liabilities. The cash flow from operating activities showed a negative trend with -3.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, while Ishita Drugs has shown growth in sales and profits, the cash flow situation indicates challenges that may need addressing.